Ipriflavone (INN, JAN; brand name Yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption,[2] maintain bone density and to prevent osteoporosis in postmenopausal women.[1] It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.
Clinical data | |
---|---|
Trade names | Yambolap |
Other names | FLI13; 7-Isopropoxyisoflavone[1] |
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.125.854 |
Chemical and physical data | |
Formula | C18H16O3 |
Molar mass | 280.323 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.[3]
A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.[4]
Ipriflavone has been described as a phytoestrogen.[5] However, this is incorrect, as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women.[6][7] The drug prevents bone loss via mechanisms that are distinct from those of estrogens.[5]